IN8BIO, Inc.

INAB Nasdaq SEC CIK 1740279
Follow IN8BIO Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$4.8M +6.1% vs same quarter last year
EPS, diluted −$0.25 +79.8% vs same quarter last year
Operating cash flow −$3.7M +4.6% vs same quarter last year
Operating income −$4.8M +6.1% vs same quarter last year
Net income by quarter
−$7.1M
−$6.2M
−$5.6M
−$5.1M
−$3.9M
−$4.9M
−$5.1M
−$4.8M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$19.4M
FY24−$30.4M
FY23−$30M
FY22−$28.5M
FY21−$14.7M
FY20−$8.6M
FY19-

News

No stories filed under IN8BIO yet - coverage appears here as the news feed clusters it.